These ‘PM p53’ tumors resemble authentic TP53‐mutated ER+Her2‐ breast tumors not only in their gene expression and pathway deregulation profiles, but also in their highly proliferative nature and shorter patient survival. The gene discussed is TP53; the disease is breast neoplasm.